CA3026143A1 - Methods and compositions for treatment of hypercalciuria and nephrolithiasis - Google Patents

Methods and compositions for treatment of hypercalciuria and nephrolithiasis Download PDF

Info

Publication number
CA3026143A1
CA3026143A1 CA3026143A CA3026143A CA3026143A1 CA 3026143 A1 CA3026143 A1 CA 3026143A1 CA 3026143 A CA3026143 A CA 3026143A CA 3026143 A CA3026143 A CA 3026143A CA 3026143 A1 CA3026143 A1 CA 3026143A1
Authority
CA
Canada
Prior art keywords
vitamin
composition
container
effective amount
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3026143A
Other languages
English (en)
French (fr)
Inventor
Eduardo I. Canto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ana Pharmaceuticals Inc
Original Assignee
Ana Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ana Pharmaceuticals Inc filed Critical Ana Pharmaceuticals Inc
Publication of CA3026143A1 publication Critical patent/CA3026143A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Pediatric Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3026143A 2016-06-02 2017-06-01 Methods and compositions for treatment of hypercalciuria and nephrolithiasis Pending CA3026143A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344653P 2016-06-02 2016-06-02
US62/344,653 2016-06-02
PCT/US2017/035514 WO2017210467A1 (en) 2016-06-02 2017-06-01 Methods and compositions for treatment of hypercalciuria and nephrolithiasis

Publications (1)

Publication Number Publication Date
CA3026143A1 true CA3026143A1 (en) 2017-12-07

Family

ID=60479095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026143A Pending CA3026143A1 (en) 2016-06-02 2017-06-01 Methods and compositions for treatment of hypercalciuria and nephrolithiasis

Country Status (14)

Country Link
US (1) US20200315233A1 (https=)
EP (1) EP3463322A4 (https=)
JP (2) JP2019517482A (https=)
AU (1) AU2017274438A1 (https=)
BR (1) BR112018075067A2 (https=)
CA (1) CA3026143A1 (https=)
CO (1) CO2018013999A2 (https=)
CR (1) CR20180576A (https=)
DO (1) DOP2018000265A (https=)
EC (1) ECSP19000167A (https=)
MX (2) MX2018014933A (https=)
NI (1) NI201800126A (https=)
TW (1) TW201808271A (https=)
WO (1) WO2017210467A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806225B (zh) * 2019-03-16 2021-06-01 西安安健药业有限公司 维生素k1脂肪乳注射液
CN112438967A (zh) * 2019-08-27 2021-03-05 高兵 维生素k在制备泌尿系结石防治药物和保健品中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446024C2 (de) * 1994-12-22 1997-01-23 Bartz Volker Verwendung eines Vitamins der K-Gruppe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CN1322530A (zh) * 2000-05-09 2001-11-21 詹炳炎 一种防治泌尿系结石的药物——尿石净
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
AU2003237371A1 (en) * 2002-06-05 2003-12-22 Transform Pharmaceuticals, Inc. High-throughput methods and systems for screening of compounds to treat/prevent kidney disorders
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US20080220094A1 (en) * 2006-11-01 2008-09-11 Wyeth Compositions and methods for the treatment and/or prevention of osteoporosis
RU2454997C2 (ru) * 2007-07-24 2012-07-10 Виридис Байофарма Пвт Лтд. Лечение болезненных состояний и заболеваний человека с использованием аналогов и производных витамина к
ES2669004T3 (es) * 2009-09-14 2018-05-23 Nestec S.A. Composiciones nutricionales para modular la inflamación, que incluyen vitamina K2 exógena
US20110229587A1 (en) * 2009-09-24 2011-09-22 Algaecal Distribution Inc. Calcium Supplements for the Treatment of Diabetes
EP2601168A4 (en) * 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US20150359807A1 (en) * 2014-06-11 2015-12-17 Supernutrition Life-Extension Research, Inc. Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof

Also Published As

Publication number Publication date
CR20180576A (es) 2019-04-09
ECSP19000167A (es) 2019-01-31
NI201800126A (es) 2019-03-28
EP3463322A4 (en) 2019-11-20
DOP2018000265A (es) 2019-04-30
JP2022153651A (ja) 2022-10-12
JP2019517482A (ja) 2019-06-24
CO2018013999A2 (es) 2019-03-08
AU2017274438A1 (en) 2018-12-13
WO2017210467A1 (en) 2017-12-07
TW201808271A (zh) 2018-03-16
MX2022013681A (es) 2022-12-13
MX2018014933A (es) 2019-04-09
US20200315233A1 (en) 2020-10-08
EP3463322A1 (en) 2019-04-10
BR112018075067A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
US5932624A (en) Vitamin supplement composition
US20180008665A1 (en) Methods of treating and preventing gout and lead nephropathy
CA3113376A1 (en) Compositions for reducing serum uric acid
US11026906B2 (en) Pharmaceutical quality strontium L-lactate
WO2014038630A1 (ja) セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品
JP2022153651A (ja) 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
JP2022500485A (ja) グラピプラント単位剤形
CN106456646A (zh) 用于治疗或预防肾结石症的可可碱或其衍生物
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
DK165966B (da) Forbedret piroxicamholdigt anti-inflammatorisk praeparat
JP3604710B2 (ja) 骨粗鬆症予防及び治療剤
AU2018327614B2 (en) Composition for calcium supplementation
JP2012522019A (ja) 腸管前処置のための組成物およびその使用方法
JPH11209303A (ja) 腎不全治療薬及び腎不全患者用食品
EP0919239A1 (fr) Composition pour le traitement des gastro-entérites aigues, comprenant une solution de réhydratation avec un composé à action synérgique
JPS5938204B2 (ja) 再生不良性貧血治療剤
WO2012156502A2 (en) Two component mouth rinse preparation
RU2616522C2 (ru) Фармацевтическая композиция для профилактики или лечения гиперлипидемии
CN107281192A (zh) 一种减轻、治疗及预防类风湿性关节炎的组合物
US10105375B2 (en) Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
JP6490742B2 (ja) 内服用組成物
JP6385642B2 (ja) 内服用組成物
CN100406064C (zh) 用于治疗由幽门螺杆菌感染引起的疾病的制剂
JPWO2011034006A1 (ja) 血液中の尿酸値を低下させるための組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220525